These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 7147981)
21. [The combination of psoriasis with different types of lipoproteinemias. 2. The characteristics of the dyslipoproteinemias caused by disorders in triacylglyceride transport in psoriasis]. Keshileva ZB; Kosukhin AB; Polevaia LG Vestn Dermatol Venerol; 1990; (5):7-11. PubMed ID: 2402946 [TBL] [Abstract][Full Text] [Related]
22. [Antithrombogenic activity of the vascular wall, hemostasis, and rheological characteristics of blood in patients with unstable angina pectoris and various types of hyperlipoproteinemia]. Kirichuk VF; Voskoboĭ IV Ter Arkh; 2000; 72(12):47-50. PubMed ID: 11201832 [TBL] [Abstract][Full Text] [Related]
23. [Effect of fish oils on plasma lipid risk factors and esterified fatty acids in primary hyperlipoproteinemia]. Zák A; Zeman M; Tvrzická E Sb Lek; 1997; 98(3):213-24. PubMed ID: 9601814 [TBL] [Abstract][Full Text] [Related]
24. [Subfractions of HDL cholesterol. Occurrence in hyperlipoproteinemia type IIa and IV]. Mertz DP; Thuilot G; Bürvenich K Fortschr Med; 1986 Jul; 104(26):508-10. PubMed ID: 3744260 [No Abstract] [Full Text] [Related]
25. Pirifibrate in the treatment of hyperlipoproteinemias: a multicenter study. Domingo AJ; Gutiérrez JA; Menéndez JA; Micó L; Muñoz M; de Oya M Clin Ther; 1980; 3(3):219-26. PubMed ID: 7459931 [TBL] [Abstract][Full Text] [Related]
26. [Effects of fenofibrate in four types of hyperlipoproteinaemia and on apoproteins A and B in type IIa HLP (author's transl)]. Micheli H; Pometta D; Gustafson A Nouv Presse Med; 1980 Dec; 9(49):3759-62. PubMed ID: 7208343 [TBL] [Abstract][Full Text] [Related]
27. The effect of n-3 fatty acids on lipids and haemostasis in patients with type IIa and type IV hyperlipidaemia. Schmidt EB; Ernst E; Varming K; Pedersen JO; Dyerberg J Thromb Haemost; 1989 Sep; 62(2):797-801. PubMed ID: 2814927 [TBL] [Abstract][Full Text] [Related]
28. Platelet activity in vivo in hyperlipoproteinemia--importance of combined hyperlipidemia. Bröijersén A; Hamsten A; Eriksson M; Angelin B; Hjemdahl P Thromb Haemost; 1998 Feb; 79(2):268-75. PubMed ID: 9493574 [TBL] [Abstract][Full Text] [Related]
29. High density lipoprotein and arteriosclerosis. Different patterns in primary hypothyroidism and type IIa hyperlipoproteinemia. Brook JG; Aviram M; Luboshitzky R; Barzilai D Isr J Med Sci; 1981 May; 17(5):318-22. PubMed ID: 7263188 [TBL] [Abstract][Full Text] [Related]
30. Platelet sensitivity to prostacyclin and thromboxane production in hyperlipidemic patients. Strano A; Davì G; Averna M; Rini GB; Novo S; Di Fede G; Mattina A; Notarbartolo A Thromb Haemost; 1982 Aug; 48(1):18-20. PubMed ID: 6753232 [TBL] [Abstract][Full Text] [Related]
31. Oxidative burst and lysosomal enzyme release by polymorphonuclear cells in type IIa, type IIb and type IV primary hyperlipoproteinaemia. Ventura MT; Puzziferri I; Tortorella C; Resta F; Capurso A; Antonaci S Recenti Prog Med; 1993; 84(7-8):503-10. PubMed ID: 8356303 [TBL] [Abstract][Full Text] [Related]
32. [Changes in serum lipoproteins in patients with ischemic heart disease at an early age]. Malamov E; Kiriakov A; Tsenov I; Kavrukova Iu; Kusitasev G Vutr Boles; 1982; 21(2):91-8. PubMed ID: 7101895 [TBL] [Abstract][Full Text] [Related]
33. [Changes in the level of certain hemostatic factors during treatment with lovastatin in patients with primary hyperlipoproteinemia and phenotype IIa and IIb]. Idzior-Waluś B Przegl Lek; 1992; 49(10):334-9. PubMed ID: 1308287 [TBL] [Abstract][Full Text] [Related]
34. [Clinical characteristics of primary hyperlipoproteinemia type IV. An analysis of 86 patients]. Kusić M; Gavrilović M; Mihajlović M; Marković N Zb Vojnomed Akad; 1981; 23():15-9. PubMed ID: 6963834 [TBL] [Abstract][Full Text] [Related]
35. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia. Guyton JR; Brown BG; Fazio S; Polis A; Tomassini JE; Tershakovec AM J Am Coll Cardiol; 2008 Apr; 51(16):1564-72. PubMed ID: 18420099 [TBL] [Abstract][Full Text] [Related]
36. Changes in lipids and lipoproteins in patients with hyperlipidemia type IIb, IV and V treated with different lipid lowering drugs. Hutt V; Wechsler JG; Klör HU; Ditschuneit H Artery; 1980; 8(2):113-9. PubMed ID: 7458676 [TBL] [Abstract][Full Text] [Related]
37. [Juvenile xanthogranuloma in an infant in combination with familial hyperlipoproteinemia (author's transl)]. László A; Korom I; Szilágyi I; Kahán-László I; Fáy P Z Hautkr; 1981 Feb; 56(3):156-62. PubMed ID: 6784365 [TBL] [Abstract][Full Text] [Related]
38. [Fenofibrate: hypolipaemic activity and safety in long-term treatment. Effects on HDL, LDL, VLDL and apoprotein B in short-term treatment (author's transl)]. Rouffy J; Sauvanet JP; Chanu B; Bakir R; Goy-Loeper J; Saya C; Pinaroli F Nouv Presse Med; 1980 Dec; 9(49):3747-51. PubMed ID: 7208341 [TBL] [Abstract][Full Text] [Related]
39. [Functional status of thrombocytes and the anti-aggregative activity of the vascular wall in dyslipoproteinemias and ischemic heart disease]. Mikhailova IA; Lipovetskiĭ BM; Magracheva EIa; Gurevich VS Ter Arkh; 1989; 61(2):101-4. PubMed ID: 2727909 [TBL] [Abstract][Full Text] [Related]
40. Levels of sICAM-1, sVCAM-1 and MCP-1 in patients with hyperlipoproteinemia IIa and -IIb. Kowalski J; Okopien B; Madej A; Makowiecka K; Zielinski M; Kalina Z; Herman ZS Int J Clin Pharmacol Ther; 2001 Feb; 39(2):48-52. PubMed ID: 11270801 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]